Parkinson's Disease
March 2022 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Parkinson's Disease abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Parkinson's Disease. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Parkinson's Disease. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Parkinson's Disease every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Parkinson's disease: Alterations of motor plasticity and motor learning.
Authors:Udupa K, Bhattacharya A, Bhardwaj S, Pal PK, Chen R
Institution:Department of Neurophysiology, National Institute of Mental Health & Neurosciences, Bengaluru, India. Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Division of Brain, Imaging and Behavior, The Edmond J. Safra Program in Parkinson's Disease, Krembil Research Institute, Toronto, ON, Canada. Electronic address:
Journal:Handb Clin Neurol. 2022;184:135-151. doi: 10.1016/B978-0-12-819410-2.00007-2.

2:Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease.
Authors:Grosso Jasutkar H, Oh SE, Mouradian MM
Institution:Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, New Jersey. Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, New Jersey
Journal:Pharmacol Rev. 2022 Jan;74(1):207-237. doi: 10.1124/pharmrev.120.000133.

3:Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations.
Authors:Berger AA, Robinson C, Winnick A, Izygon J, Jacob BM, Noonan MJ, Kaye AD, Kaye JS, Kaye AM, Cornett EM, Shah RJ, Viswanath O, Urits I
Institution:Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Journal:Clin Drug Investig. 2022 Feb;42(2):127-135. doi: 10.1007/s40261-021-01109-3. Epub 2021 Dec 21.

4:Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Authors:Blesa J, Foffani G, Dehay B, Bezard E, Obeso JA
Institution:HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
Journal:Nat Rev Neurosci. 2022 Feb;23(2):115-128. doi: 10.1038/s41583-021-00542-9. Epub 2021 Dec 14.

5:Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis.
Authors:Severiano E Sousa C, Alarcão J, Pavão Martins I, Ferreira JJ
Institution:Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal; Instituto de Medicina Molecular Joao Lobo Antunes, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal. Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal; Instituto de Medicina Molecular Joao Lobo Antunes, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal; CNS - Campus Neurologico, Bairro St. Antonio 2560-280, Torres Vedras, Portugal. Electronic address:
Journal:J Neurol Sci. 2022 Jan 15;432:120077. doi: 10.1016/j.jns.2021.120077. Epub 2021 Dec 3.

6:Protective effect of olive leaves phenolic compounds against neurodegenerative disorders: Promising alternative for Alzheimer and Parkinson diseases modulation.
Authors:Hadrich F, Chamkha M, Sayadi S
Institution:Environmental Bioprocesses Laboratory, Center of Biotechnology of Sfax, P.O. Box 1177, 3038, Sfax, Tunisia. Electronic address: Biotechnology Program, Center of Sustainable Development, College of Arts and Sciences, Qatar University, Doha, 2713, Qatar. Electronic address:
Journal:Food Chem Toxicol. 2022 Jan;159:112752. doi: 10.1016/j.fct.2021.112752. Epub 2021 Dec 3.

7:Antioxidative role of Traditional Chinese Medicine in Parkinson's disease.
Authors:Muhammad F, Liu Y, Zhou Y, Yang H, Li H
Institution:College of Life Sciences, Lanzhou University, Lanzhou, China. College of Life Sciences, Lanzhou University, Lanzhou, China; School of Pharmacy, Lanzhou University, Donggang West Road No. 199, Lanzhou, 730020, China. Electronic address:
Journal:J Ethnopharmacol. 2022 Mar 1;285:114821. doi: 10.1016/j.jep.2021.114821. Epub 2021 Nov 25.

8:Respiratory disorders of Parkinson's disease.
Authors:Aquino YC, Cabral LM, Miranda NC, Naccarato MC, Falquetto B, Moreira TS, Takakura AC
Institution:Department of Pharmacology, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, Brazil.
Journal:J Neurophysiol. 2022 Jan 1;127(1):1-15. doi: 10.1152/jn.00363.2021. Epub 2021 Nov 24.

9:Parkinson's disease and COVID-19: a systematic review and meta-analysis.
Authors:Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, Mirmosayyeb O
Institution:Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Journal:Neurol Sci. 2022 Feb;43(2):775-783. doi: 10.1007/s10072-021-05756-4. Epub 2021 Nov 17.

10:Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review.
Authors:Oedekoven C, Egeri L, Jessen F, Wagner M, Dodel R
Institution:Chair of Geriatric Medicine, University Duisburg-Essen, Center for Translational Neurological and Behavioural Research, University Hospital, University Duisburg-Essen, Germany. Electronic address:
Journal:Ageing Res Rev. 2022 Feb;74:101508. doi: 10.1016/j.arr.2021.101508. Epub 2021 Nov 3.

11:Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Authors:Kurihara K, Mishima T, Fujioka S, Tsuboi Y
Institution:Department of Neurology, Fukuoka University Fukuoka, Japan.
Journal:Expert Opin Drug Saf. 2022 Feb;21(2):137-147. doi: 10.1080/14740338.2022.1988926. Epub 2021 Oct 15.

12:A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value.
Authors:Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch EE, Bertino G, Cereda E, Clavè P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese Ragona R, Masiero S, Michou E, Occhini A, Pacchetti C, Pfeiffer RF, Restivo DA, Rondanelli M, Ruoppolo G, Sandrini G, Schapira AHV, Stocchi F, Tolosa E, Valentino F, Zamboni M, Zangaglia R, Zappia M, Tassorelli C, Alfonsi E
Institution:Department of Brain and Behavioral Sciences, University of Pavia, Via Mondino 2, 27100, Pavia, Italy. Clinical Neurophysiology Unit, IRCCS Mondino Foundation, Pavia, Italy.
Journal:J Neurol. 2022 Mar;269(3):1335-1352. doi: 10.1007/s00415-021-10739-8. Epub 2021 Aug 21.

13:The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis.
Authors:El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA
Institution:Faculty of Medicine, Minia University, Minia, Egypt. Neuroradiology and Neurointervention Service, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Journal:Rev Med Virol. 2022 Mar;32(2):e2278. doi: 10.1002/rmv.2278. Epub 2021 Jul 14.

14:Treatment of Advanced Parkinson's Disease.
Authors:Gilbert R, Khemani P
Institution:American Parkinson Disease Association, New York, NY, USA. Swedish Neuroscience Institute, Seattle, WA, USA.
Journal:J Geriatr Psychiatry Neurol. 2022 Jan;35(1):12-23. doi: 10.1177/0891988720988904. Epub 2021 Jan 29.

For a FREE PREVIEW of the Medifocus Guidebook on Parkinson's Disease click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Parkinson's Disease click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Parkinson's Disease...
at a Special 20% Discount

Medifocus Guidebook on Parkinson's Disease

Updated: January 3, 2022
193 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Parkinson's Disease is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $49.95
  • Less 20% Discount = - $10.00
  • Discounted Price = $39.95(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $34.95
  • Less 20% Discount = - $7.00
  • Discounted Price = $27.95

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: January 10, 2023

What Our Customers Are Saying...

"I ordered the MediFocus Guidebook on Parkinson's Disease for my father who has had this condition for about 15 years. It was extremely useful to learn about the medications that are used to treat Parkinson's as well as the side-effects. I had read a lot of articles about Parkinson's on the Internet but they were all very general and vague. Your Guidebook provided excellent and comprehensive information from the medical perspective. Thanks for a very useful resource that is much needed today on the Web."
Russelsheim, Germany

"I found your Guidebook on Parkinson's to be very informative for me, the patient, and for my husband. I am in the process of changing my medication and the book explained more to me than the doctor attempted to. I am now more aware of what to expect. It also offered valuable advice for the caregiver. Thank you."
Palm Spring, California

"The Medifocus Guide to Parkinson's Disease was useful, informative, and allowed me to grasp the current fundamentals of treatment. I have recommended it to two of my ex-patients whom I know will find it readable and helpful to their needs."
Research Triangle Park, NC

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2022 Medifocus, Inc. All rights reserved.